Adapted RPM-08 for Substance Use Disorder in Pakistan
Summary
This ClinicalTrials.gov registration (NCT07552623) describes an eight-week randomized controlled trial in Pakistan testing whether a culturally adapted Relapse Prevention Module (RPM-08) combined with usual treatment reduces relapse risk in adults with substance use disorders, compared to usual treatment alone. Participants will attend eight structured group sessions and complete questionnaires at baseline, post-intervention, and follow-up to assess whether the adapted intervention's effects are sustained over time. This trial registration provides study design and participant information but does not impose compliance obligations on regulated entities.
“The goal of this clinical trial is to learn if a culturally adapted Relapse Prevention Module (RPM-08) can reduce relapse risk in people with substance use disorders in Pakistan.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov study registration documents a randomized controlled trial evaluating the efficacy of a culturally adapted Relapse Prevention Module (RPM-08) in reducing relapse risk among individuals with substance use disorders in Pakistan. The study will enroll participants receiving either the adapted RPM-08 intervention plus treatment as usual or treatment as usual alone, with outcomes measured at baseline, post-intervention, and follow-up.\n\nFor clinical investigators and healthcare providers, this registration represents informational content about an upcoming research study rather than a binding regulatory action. The trial does not impose new compliance requirements or reporting obligations. Researchers studying SUD interventions, relapse prevention strategies, or cross-cultural healthcare adaptations may find this registration relevant to ongoing literature reviews or protocol development.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Adapted RPM-08 for Substance Use Disorder in Pakistan
N/A NCT07552623 Kind: NA Apr 27, 2026
Abstract
The goal of this clinical trial is to learn if a culturally adapted Relapse Prevention Module (RPM-08) can reduce relapse risk in people with substance use disorders in Pakistan. The study also examines whether the adapted intervention is effective over time.
The main questions it aims to answer are:
Does the adapted RPM-08 reduce relapse risk compared to usual treatment? Are the effects of the intervention maintained after a follow-up period?
Researchers compared participants who received the adapted RPM-08 along with usual treatment to those who received usual treatment only to see if the intervention improves relapse outcomes.
Participants will:
Attend eight structured group sessions over eight weeks Receive usual treatment provided by the rehabilitation center Complete questionnaires at baseline, after the intervention, and at follow-up
Conditions: Substance Use Disorder (SUD), Drug Abuse, Relapse
Interventions: Adapted Relapse Prevention Module (RPM-08), Treatment as Usual (TAU)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.